http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1287299-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_536b38fcd8994ba844b9e23915f439ab |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04 |
| filingDate | 1986-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1991-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_460ebfc311f153234ba6a514e06696e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2546964708fb869dd1fe80ed8b3adbc9 |
| publicationDate | 1991-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1287299-C |
| titleOfInvention | Method and compositions for reducing dysfunction in angioplasty procedures |
| abstract | A method for reducing dysfunction in angioplasty procedures and particularly, in myocardial angioplasty procedures in human beings is desired. The method involves the introductlon of a selected amount of intra-arterial prostaglandin compound into an artery, such as a coronary artery, in which an angioplasty procedure is to occur. The prostaglandin compound will provide cyto-protection and provide antithrombotic effects and antiplatelet effects and antispasmatic effects. The prostaglandin compound is administered in a pharmacological amount, that is, an amount substantially greater than the prostaglandin which would be generated by a normal myocardial artery when insulted and thus, constitutes an administration substantially greater than an amount which would be administered in a replacement therapy. A composition is also provided for reducing dysfunction in angioplasty procedures and comprises a selected amount of a carrier and a prostaglandin compound carried in a specified amount and which carrier does not alter the prostaglandin compound and releases the prostaglandin compound at a rate sufficient to dilate blood vessels to thereby produce the required efficacy. A prepackaged combination of components provides for the complete administration of the prostaglandin compound before, during and after the angioplasty procedure. |
| priorityDate | 1985-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.